大理药业(603963) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥39,816,703.15, representing a decrease of 18.74% compared to the same period last year[4] - The net profit attributable to shareholders was a loss of ¥3,207,503.31, reflecting a significant decline of 1,791.60% year-over-year[4] - The basic and diluted earnings per share were both -¥0.0146, a decrease of 1,722.22% compared to the previous year[4] - Total operating revenue for Q1 2022 was ¥39,816,703.15, a decrease of 18.7% compared to ¥48,999,329.56 in Q1 2021[16] - Net profit for Q1 2022 was a loss of ¥3,207,503.31, compared to a profit of ¥189,613.98 in Q1 2021[17] - Total revenue from sales of goods and services in Q1 2022 was 41,070,778.00 RMB, down 21.5% from 52,425,098.38 RMB in Q1 2021[20] - The company incurred a net loss attributable to the parent company of -3,207,503.31 RMB in Q1 2022, compared to a profit of 189,613.98 RMB in Q1 2021[18] - Basic and diluted earnings per share for Q1 2022 were both -0.0146 RMB, a significant decrease from 0.0009 RMB in Q1 2021[18] Assets and Liabilities - The total assets at the end of the reporting period were ¥532,763,510.03, down 2.91% from the end of the previous year[5] - Total assets as of March 31, 2022, were ¥532,763,510.03, down from ¥548,746,054.41 at the end of 2021[15] - Total liabilities decreased to ¥117,113,108.65 in Q1 2022 from ¥129,888,149.72 in Q1 2021, a reduction of 9.9%[14] - Current assets totaled ¥336,026,750.19, a decrease of 3.5% from ¥348,545,191.59 at the end of 2021[13] - Cash and cash equivalents were ¥65,639,521.27, down from ¥180,658,755.50 at the end of 2021[12] - Cash and cash equivalents at the end of Q1 2022 were 65,639,521.27 RMB, a decrease from 180,658,755.50 RMB at the beginning of the quarter[22] Cash Flow - The cash flow from operating activities showed a net outflow of ¥6,173,987.51, indicating a decrease in cash received from sales[4] - In Q1 2022, the company reported a net cash flow from operating activities of -6,173,987.51 RMB, compared to -1,901,446.89 RMB in Q1 2021, indicating a decline in operational cash flow[21] - The total cash outflow from operating activities was 47,748,765.07 RMB in Q1 2022, compared to 55,509,429.77 RMB in Q1 2021, reflecting a reduction in cash outflow[21] - The company received 503,999.56 RMB in other cash related to operating activities in Q1 2022, down from 1,182,884.50 RMB in Q1 2021[21] - Cash outflow from financing activities in Q1 2022 was -573,813.76 RMB, a significant decrease from a net inflow of 9,705,722.22 RMB in Q1 2021[22] Investments - The company reported a significant decrease in cash and cash equivalents by 63.67%, primarily due to investments in financial products[7] - The company experienced a 76.68% increase in trading financial assets, attributed to the same investment strategy[7] - The company invested 100,000,000.00 RMB in Q1 2022, compared to no investment in Q1 2021, indicating a strategic shift towards investment activities[21] - The company reported a net cash flow from investing activities of -108,271,432.96 RMB in Q1 2022, compared to -5,657,380.27 RMB in Q1 2021, indicating increased investment expenditures[21] Operational Metrics - Total operating costs for Q1 2022 were ¥44,198,473.44, down 13.0% from ¥50,787,850.90 in Q1 2021[16] - The company reported a gross profit margin of -10.4% in Q1 2022, compared to a positive margin in Q1 2021[16] - Inventory decreased to ¥22,932,220.87 from ¥25,420,333.37, a decline of 9.8%[13] - Research and development expenses increased to ¥347,576.35 in Q1 2022 from ¥286,045.07 in Q1 2021, reflecting a growth of 21.5%[16] Government Support and Strategic Direction - The company received government subsidies amounting to ¥44,176.20 during the reporting period[6] - The company has not disclosed any new product developments or market expansion strategies in this report[11]